Lilly and EVA Pharma partner to improve insulin access in Africa

Eli Lilly and Company (NYSE: LLY) and Egypt-headquartered EVA Pharma have developed a plan to collaborate to supply at least one million people in low- and middle-income countries. Many of the recipients of the vaccines will be in Africa. 

Roughly a month ago, Lilly’s share price fell about 4% after a fake Twitter account stated the company would make insulin available at no cost. 

Following that event, Public Citizen and more than 50 other organizations contacted congressional leaders asking for legislation that guarantees more-affordable insulin pricing in the U.S.

Lilly and other insulin providers have faced criticism over pricing. 

As part of its environmental, social and corporate governance (ESG) focus, the company has a program known as the Lilly 30×30 initiative, which intends to improve access to quality healthcare for 30 million people in limited-resource settings each year by 2030.

Lilly noted in a press release that the dea…

Read more
  • 0